Research
Sleep disorders are increasingly prevalent in today’s society, and have a large economic and social impact. Our research primarily focuses on the two most common sleep disorders - insomnia and obstructive sleep apnoea. We conduct 1) laboratory-based studies to explore the mechanisms underlying cognitive and mood dysfunction in these patients, and 2) clinical trials to examine the impact of novel treatments on cognition and mood outcomes.
Areas of research/projects
Sleep, Heart and Brain project (SHEBA)
Obstructive sleep apnoea and hypertension are highly prevalent and commonly co-occur. Both conditions, if left untreated, can significantly impact brain health and impair cognition. Our team have shown that OSA is associated with cognitive impairment, brain shrinkage and higher levels of the neurotoxic protein, beta-amyloid, compared to healthy individuals. In this project, we are examining cognition and blood-based biomarkers of neurodegeneration (beta-amyloid and tau) to determine if there are poor brain and cognitive outcomes in those OSA patients with a vascular risk factor. Early identification and treatment of OSA may be a target to slow neural and cognitive impairment, before it progresses to dementia.
Sound Asleep Trial
(NHMRC Ideas grant 2024-2027)
Obstructive Sleep Apnoea (OSA) is a highly prevalent disorder, with an economic cost in excess of AU$18.9 billion annually. It is caused by repetitive collapse of the airway during sleep, resulting in dramatic drops in blood oxygen
levels and sleep disruption. One aspect of sleep that is critical for effective cognition is the presence of slow wave sleep; a deep, stable phase of Non-REM sleep. We have shown that individuals with OSA have less slow wave sleep, poorer cognition and brain atrophy compared to healthy individuals. Notably, OSA is a risk factor for mild cognitive impairment and dementia. Thus, it is critical to treat OSA, particularly from mid-life, to prevent further cognitive decline. Current OSA treatments are poorly tolerated and only partially effective; thus, novel treatments are urgently needed.
Acoustic stimulation therapy has been used in healthy adults across the lifespan to improve slow wave sleep, with positive benefits for cognition. In this first-of-its-kind NHMRC-funded project, we will explore the use of acoustic stimulation therapy in individuals with OSA. OSA patients will undergo two weeks using an acoustic stimulation device - one week each in active and sham mode, in a randomised order. Polysomnography, daytime sleepiness and cognition will be assessed to determine if acoustic stimulation therapy can bolster slow wave sleep, improve cognition and sleepiness, and alter OSA pathophysiology. We will also assess the feasibility of acoustic stimulation therapy for use in individuals with OSA. This study will take the first steps in determining whether acoustic stimulation therapy enhances slow wave activity, and improves daytime functioning and OSA severity; thus offering a unique, cost-effective, and non-invasive alternative treatment for the millions of individuals with OSA who remain untreated.
Mindfulness Intervention for Insomnia, Mood and Cognition (MindMInC) Trial
Sleep difficulties are highly prevalent in older adults but often go untreated as they are considered a sign of normal ageing. Sleep difficulties are also linked to increased feelings of stress, anxiety, depression and issues with memory and concentration. For many individuals, improving sleep can enhance their wellbeing. However, not many seek these alternative treatments due to barriers like time constraints, geographical access, long waitlists and limited availability.
This study aims to investigate the feasibility of an online mindfulness-based intervention for insomnia for older adults with sleep difficulties compared to a sleep hygiene program. This will help to understand whether such interventions are a helpful way to enhance wellbeing and overcome barriers to accessing sleep treatments for older adults.
We are inviting adults aged 55+ with sleep difficulty to access an online insomnia program for better sleep in this Monash University led study.
Please check our website for more information: https://basemindfulsleep.wixsite.com/mindminc-study
Sleep interventions for older adults and carers: Care2Sleep project
(MRFF funding 2024-2029)
Sleep disturbances are common in individuals with cognitive decline and their carepartners. Despite this, effective and accessible treatments of sleep disturbances remain an unsolved challenge. In our previous work we designed and tested a 6-week sleep intervention, the Better Sleep for Wellbeing Program, which led to significant improvements in insomnia and mental health symptoms in community-dwelling individuals living with mild cognitive impairment (MCI) or dementia and their carepartners. Our next aim is to expand the availability of this existing intervention into a scalable, accessible, low-cost format. In light of this, we are running co-design workshops to gain valuable feedback from a range of community panels (i.e., people living with MCI or mild dementia, carepartners, advocacy groups, sleep professionals, etc.) on the design of a digital self-directed sleep program, supported by trained sleep coaches, for use by people living with MCI or mild dementia and their carepartners. We then hope to deliver this digital sleep program to the community and test its effectiveness.
BLINKS-AD
Alzheimer’s Disease (AD) is the leading cause of dementia and affects over 400,000 Australians. AD is characterised by progressive cognitive decline, including impairments to memory, executive function, attention, and processing speed. These deficits contribute to loss of independence, increased mortality, and reduced quality of life.
Beyond cognition, a growing body of research also suggests that AD is also associated with chronic, persistent, (trait) sleepiness and increased transient, situational (state) sleepiness. While individuals with AD exhibit pronounced sleepiness, it is also observable in individuals with Mild Cognitive Impairment (MCI), a condition considered to be an intermediate stage between healthy aging and AD. These abnormal levels of sleepiness are associated with increased accident risks, chronic fatigue, and reduced potentially performance on neuropsychological tests. Despite this, there is currently no validated clinical tool to assess sleepiness in individuals across the AD continuum. The influence of sleepiness on cognition also remains unclear.
There is emerging evidence that ocular biomarkers, such as spontaneous eye blink (SEB), may provide an objective, non-invasive measure of trait and state sleepiness. However, research exploring their application in MCI and AD remains limited. The BLINKS-AD study aims to provide proof-of-concept data on the utility of eye blink measures in assessing sleepiness in these populations.